Commentary · 21 Feb 2026
Conference abstractPublished 28 Sep 2015
Design, synthesis and biological evaluation dual inhibitors targeting G9a and HDAC as novel anticancer agents
Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
DNA is packaged with chromatin within the cell, the nucleosome is the fundamental unit of chromatin and it is composed of an octamer of the four core histones (H3, H4, H2A, H2B) around which 147 base pairs of DNA are wrapped. Posttranslational modifications(PTM) of histone tails such as acetylation, methylation, phosphorylation, ubiquitylation, and sumoylation play important roles in epigenetic regulation[1]. These modifications are maintained by the relative activities of sequence-specific writers and erasers, with aberrant enzymatic activities or expression profiles closely correlated with multiple human Diseases. In this work we focused on developing a dual inhibitor targeting two PTMs: histone H3 lysine 9 (H3K9) methylation promoted by G9a and the overall histone deacetylation promoted by HDAC(Fig.1). These modifications are directly correlated with many cancers including leukemia, prostate carcinoma, hepatocellular carcinoma and lung cancer[2, 3]. In this work we bring forward a single molecule possesses the pharmacophore of a G9a inhibitor and HDAC inhibitor by substituting the lipophilic cap of the HDAC inhibitor with a G9a inhibitor core(Fig.2). Complex diseases like cancer have a multifactorial basis that involves both genetic and environmental risk factors, a balanced modulation of several therapeutic targets can provide a superior therapeutic effect and a lowered side effect profile compared with monotherapies. 1.Kouzarides, T., Chromatin modifications and their function. Cell, 2007. 128(4): p. 693-705. 2.Liu, F., et al., Discovery of an in vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP. Journal of medicinal chemistry, 2013. 56(21): p. 8931-8942. 3.Batty, N., G.G. Malouf, and J.P.J. Issa, Histone deacetylase inhibitors as anti-neoplastic agents. Cancer letters, 2009. 280(2): p. 192-200.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Muhammed ShukkoorKondengaden”
- BylineArticles whose byline prints “LanlanZang”
- BylineArticles whose byline prints “Shanshan Li”
- BylineArticles whose byline prints “Kenneth huang”
- BylineArticles whose byline prints “Peng George Wang”
